Bevacizumab (Avastin, genentech , Inc., San Francisco, California, the USA) is a drug, approved by the FDA for the treatment of the metastatic colorectal cancer(2). It consists of a humanized monoclonal antibody that binds all active forms of VEGF (3,18,19), blocking the activity of its two receptors (4). In the last years its use "off-label", in ophthalmology field, has become popular. This is due to its proven safeness and effectiveness for the treatment of diverse ocular diseases (2-4,7,20). Within the ophthalmic pathologies that have been treated successfully with the Intravitreal administration of Bevacizumab, we can mention different Neovascular pathologies (diabetic Retinopathy (9,18), age related macular degeneration(2,4,18)) and pathologies that alter the vascular permeability (macular edema (4,7), Central and branch retinal vein occlusion (3,8,20), central serous choroidopathy). In all of them , treatment responses is characterized by an improvement of the visual acuity, decrease of macular thickness and improvement of the angiographic patterns (8,10). The potential complications of the use of Bevacizumab are the severe thromboembolic event, arterial hypertension (18), epistaxis, proteinuria,hemoptysis, alteration in wound healing and gastrointestinal bleed (4,10).